BIO Wants Expanded Accelerated Approval In PDUFA Instead Of Progressive Approval
This article was originally published in The Pink Sheet Daily
While it would not grab as much attention as creating a whole new approval pathway, BIO believes tinkering with accelerated approval to give the regulations more clarity and increase its use still could generate the change it wants at FDA.
You may also be interested in...
Next iteration of user fee legislation could include reducing amount of data sponsors must collect; 21st Century Cures initiative represents ‘dry run’ that could smooth agreement, Pfizer rep says.
The number of requests to use investigational drugs outside of clinical trials has grown and FDA typically approves all requests, but advocates still insist the process is set up to fail patients.
Presidential advisory panel makes eight recommendations to improve innovation in drug discovery, development and evaluation; calls for broad partnership of stakeholders to accelerate therapeutics, $40 million annual appropriations for FDA’s Sentinel System.